

1

2 **AEROSOL GENERATION DURING COUGHING - QUANTITATIVE DEFINITION FOR**

3 **AEROSOL GENERATING PROCEDURES: OBSERVATIONAL STUDY** PhD, ENNI

4 SANMARK^{1,2}, MD, LOTTA-MARIA A.H. OKSANEN^{1,2}, MSc NOORA RANTANEN^{1,2}, MD

5 MARI LAHELMA^{1,2,3}, Dosent, VELI-JUKKA ANTTILA^{1,4}, Professor, LASSE LEHTONEN^{1,5},

6 Dosent, ANTTI-PEKKA HYVÄRINEN⁶, Dosent, AHMED GENEID^{1,2}

7 ¹ University of Helsinki, Helsinki, Finland

8 Faculty of Medicine

9 ² Helsinki University Hospital, Helsinki, Finland

10 Department of Otorhinolaryngology and Phoniatics – Head and Neck Surgery

11 ³ Faculty of Science, Mathematics and Statistics

12 ⁴ Helsinki University Hospital, Helsinki, Finland

13 HUS Inflammation Center

14 ⁵ Helsinki University Hospital, Helsinki, Finland, HUS Diagnostic Center, HUSLAB

15 ⁶Finnish Meteorological Institute, Helsinki, Finland

16

17 **Corresponding author:**

18 Enni Sanmark:

19 Address: Valhallankatu 7a 21, 00250 Helsinki

20 E-mail: enni@sanmark.fi

21 Telephone: +358-408446940

22 ORCID: 0000-0003-0209-5501

23

24

25

26 **ABSTRACT**

27

28 **Aim:** The purpose of the study was to determine aerosol exposure generated by coughing in

29 operation room environments to create a quantitative limit value for high-risk aerosol-generating

30 medical procedures.

31 **Background:** Coughing is known to produce a significant amount of aerosols and is thus commonly

32 used as a best reference for high-risk aerosol-generation. Accordingly, procedures during which

33 aerosol generation exceeds the amount of aerosol generated in instances of coughing are seen as

34 high-risk aerosol generating procedures. However, no reliable quantitative values are available for

35 high-risk aerosol-generation.

36 Methods: Coughing was measured from 37 healthy volunteers in the operating room environment.

37 Aerosol particles generated during coughing within the size range of 0.3–10 µm were measured

38 with Optical Particle Sizer from 40cm, 70cm, and 100cm distances. The distances reflected

39 potential exposure distances where personnel are during surgeries.

40 Results: A total of 306 coughs were measured. Average aerosol concentration during coughing was

41 1.580 ± 13.774 particles/cm³ (range 0.000 – 195.528).

42 Discussion: The aerosol concentration measured in this study can be used as a limit for high-risk

43 aerosol generation in the operating room environment when assessing the aerosol generating

44 procedures and the risk of operating room staff's exposure for aerosol particles.

45

46 **ABBREVIATIONS:** Aerosol generating procedure (AGP), operating room (OR)

47 **RUNNIG TITLE** Aerosol generation during coughing

48

49 **KEYWORDS** Aerosol generating procedure, COVID-19, Cough, Optical Particle Sizer, Aerosol

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72 **INTRODUCTION**

73

74 Airborne transmission has recently been recognized as an important transmission route of COVID-
75 19 as well as for many other respiratory infections such as tuberculosis and influenza [1-4].
76 Aerosol particles, which can potentially carry pathogens, are generated for example when breathing,
77 talking, and coughing, but also presumably during certain surgical procedures performed in the
78 respiratory tract area where infective pathogens are known to be found. Fear about the spread of
79 COVID-19 during surgeries has led, for example in the field of otorhinolaryngology, to
80 cancellations of surgeries, minimization of staff in the operating room (OR), and changes in
81 personal protective equipment (PPE) guidelines during the current pandemic [5-7].

82

83 Traditionally, aerosols have been defined as particles smaller than $5\mu\text{m}$ in size that can remain in
84 the air for long periods of time and spread far into space. However, environmental factors have a
85 significant effect on the dispersion of aerosols and there has been a recent debate regarding whether
86 all particles below $100\mu\text{m}$ should be considered as aerosols [8, 9]. Overall, aerosol generation is a
87 continuum from the smallest aerosols to larger droplet-sized particles, depending on source.
88 Nonetheless, smaller aerosols are present in higher number and tend to spread the farthest and
89 particles smaller than $5\mu\text{m}$ have been found to carry the majority of pathogens [10-12]. Findings
90 related to COVID-19 support this assumption: SARS-CoV-2 has been detected in particles 0.25--
91 $1.0\mu\text{m}$, $1\text{--}4\mu\text{m}$, and $> 4\mu\text{m}$. Most results are obtained by PCR, but infectious virus has also been
92 detected in viral culture [13-15]. These facts together make small ($<5\mu\text{m}$) particles most
93 challenging for infection control measures[16].

94

95 When assessing the risk of infection, the infectious dose associated with the pathogen, the time of
96 exposure and the number of pathogens should be considered. However, both infectious doses of
97 different airborne pathogens and the number of infectious pathogens contained in aerosol particles
98 are yet widely unknown and require further investigation before they can be reliably used as part of

99 a risk assessment for airborne diseases. Therefore, procedures performed in health care, such as
100 surgeries, have been classified as potentially aerosol-generating procedures (AGP) or high-risk
101 AGPs based mainly on the area to be operated and the instruments used, with no degree of
102 quantification [17, 18].

103

104 Coughing is known to produce a potentially infectious amount of aerosols and it has recently been
105 used as a quantitative reference for high-risk aerosol generation during surgeries and other clinical
106 procedures [19-21]. It could be said that the current list of aerosol generating procedures is not valid
107 as knowledge of aerosol generation has changed during the pandemic. Many questions persist about
108 quanta and epidemiology in each disease. Procedures in which aerosol generation exceeds the
109 amount of aerosol concentration produced by coughing are those that could be considered t high-
110 risk aerosol generating procedures (AGP) until further knowledge is obtained [22]. This definition
111 does not take a position on the infectious dose, but together with the exposure time provides an
112 estimate of the potential exposure to airborne pathogens

113 The amount of exposure received by OR staff during the procedure is a key factor in aerosol risk
114 assessment, rather than the total aerosol concentration generated, as highly effective ventilation
115 does lower exposure. Therefore, the purpose of our study was to determine an adequate and
116 quantitative value for high-risk AGPs from the perspective of OR staff by measuring the amount of
117 particle concentration that a person in the OR is exposed to. The results of this study can be applied
118 by comparing the concentration and size distribution of aerosol produced during surgical
119 procedures with the concentration produced by coughing and by estimating the duration of the
120 operation. In the future, as information on infectious doses of various airborne diseases increases,
121 this can be combined with risk assessment.

122

123 **METHODS** We recruited 37 healthy volunteers to cough in OR and measured the particle
124 generation during coughing. In addition, 15 patients' involuntary cough episodes were measured
125 separately when they woke up from general anesthesia or were under local anesthesia. Coughs
126 during extubations were excluded. We compared volitional and involuntary coughing to ensure that
127 there was no significant difference between these allowing a more accurate quantitative assessment
128 of volitional coughs. All measurements were conducted in the Helsinki University Hospital,
129 between December 2020 and February 2021. The ORs had Recair 4C ventilation system with
130 HEPA-14 filtration, and ultra-clean ventilation in the laminar area of 1210–1298 l/s generating 400
131 - 572,83 air changes per hour. Measurements were performed with the Optical particle sizer (OPS),
132 model TSI model 3330 measuring the size range from 0.3 to 10 μm and flow rate of 1l/min.
133
134 OPS was situated 40 cm, 70 cm, and 100cm from the volunteers to reflect the same distances and
135 thus same particle amounts which OR staff, operating physicians, or assisting nurses are exposed to
136 during surgical operations. Involuntary cough measurements were performed an average of 124 cm
137 (range 40–180 cm) from the patient. No additional collection methods, for example funnels, were
138 used to reflect the actual particle exposure in a certain spot (OR personnels' mouth) in the OR
139 environment. Volunteers were asked to cough as hard as possible for three to five times from each
140 distance. Each cough episode was measured separately ensuring that the particles from previous
141 coughs had time to clear from the OR. Coughs were directed towards the OPS device, and particle
142 concentration was measured with a 5- or 10-second scale interval. For each cough, several
143 measurements were collected for 10 seconds.

144

145 The size dependent aerosol concentrations measured with OPS were normalized with respect to the
146 sizing bin widths within 0.3 to 10 μm . The particle number size distributions and total particle
147 concentrations per cubic centimeter were calculated. The particles were categorized based on the

148 diameter as follows: $<1\ \mu\text{m}$, $1\text{--}5\ \mu\text{m}$, and $>5\ \mu\text{m}$. Due to infection risk being related to cumulative
149 aerosol exposure, the mean was calculated for each patient at each coughing distance as a statistical
150 representative. Pairwise comparisons between voluntary and involuntary coughing were calculated
151 using unpaired Student's t-test with Benjamini-Yekutieli procedure for multiple comparisons with
152 5% false discovery rate[23]. Prior comparisons the data was log₁₀ normalized. The analyses were
153 performed using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington, USA), and
154 GraphPad Prism version 9.0.2 for Mac (GraphPad Software, San Diego, California USA) or
155 RStudio version 1.3.959 (R Foundation for Statistical Computing, Vienna, Austria). Measured
156 minimum concentration in all size classes was 0.000. A p-value <0.05 was considered to be
157 statistically significant. STROBE reporting guidelines were followed when preparing the
158 manuscript.

159

160 All procedures that involved human participants were conducted in accordance with the ethical
161 standards of the institutional or national research committee and the 1964 Declaration of Helsinki
162 and its later amendments or comparable ethical standards. The Ethics Committee of Helsinki
163 University Hospital approved the study protocol (HUS/1701/2020). All participants provided
164 written informed consent prior to their participation.

165

166 **RESULTS AND ANALYSIS** A total of 306 coughs were measured from 37 healthy volunteers.
167 The detailed information about particle concentrations when coughing from different distances are
168 presented in **Table 1**. All background concentrations were very low (maximum mean total
169 concentration $0.0053\ \text{particles}/\text{cm}^3$) which enabled the accurate evaluation of particle concentration
170 generated during the procedure. The comparison of involuntary coughs from 15 patients to
171 volitional coughs are presented in **Figure 1**. Mean particle concentration during involuntary coughs
172 was $0.140\ \text{p}/\text{cm}^3 \pm 0.332$ (range $0.006\text{--}1.308$) for particles $<1\ \mu\text{m}$, $0.025\ \text{p}/\text{cm}^3 \pm 0.068$ (range

173 0.000–0.270) for particles 1–5 μm and $0.002 \text{ p/cm}^3 \pm 0.006$ (range 0.000–0.024) for particles >5
 174 μm . These measurements were compared with volitional coughs to determine whether the collected
 175 data also describes involuntary coughing. There were no significant differences between volitional
 176 and involuntary coughing at any particle size category ($p=0.244$ – 0.883).

177


178 **Table 1.** Observed particle concentration during volitional coughing from different distances

Measured cough episodes, n		All (n=74)	40 cm from source (n=37)	70 cm from source (n=15)	100 cm from source (n=22)
Total particle concentration (particles/cm³)	Median	0.055	0.055	0.026	0.070
	Mean \pm SD	1.706 ± 10.802	0.923 ± 5.078	0.091 ± 0.136	4.12 ± 18.771
	Range	0.000 – 88.157	0.013 – 30.973	0.000 – 0.466	0.016 – 88.157
<1μm particle concentration (particles/cm³)	Median	0.044	0.043	0.026	0.053
	Mean \pm SD	1.692 ± 10.791	0.906 ± 5.030	0.087 ± 0.133	4.111 ± 18.770
	Range	0.000 – 88.141	0.011 – 30.668	0.000 – 0.454	0.011 – 88.141
1–5μm particle concentration (particles/cm³)	Median	0.008	0.008	0.002	0.013
	Mean \pm SD	0.013 ± 0.035	0.017 ± 0.049	0.004 ± 0.004	0.013 ± 0.006
	Range	0.000 – 0.304	0.000 – 0.304	0.000 – 0.012	0.004 – 0.028
>5μm particle concentration (particles/cm³)	Median	0.000	0.000		0.001
	Mean \pm SD	0.001 ± 0.001	0.001 ± 0.001	NA	0.001 ± 0.001
	Range	0.000 – 0.005	0.000 – 0.005		0.000 – 0.004

179

180 SD, standard deviation.

181



182

183 **Figure 1: Volitional coughing vs. involuntary coughing.** (A) Average aerosol size distributions presented with the
184 background (dotted line) during volitional and anesthesia coughs (involuntary) expressed as mean (line) with 95%
185 confidence interval (envelopes). (B) Total concentrations and concentrations of <1µm, 1–5µm and >5µm aerosols
186 during volitional and anesthesia coughs (involuntary), presented as median with interquartile range (box) and range
187 (whiskers). Volitionally coughing patients, n=37 (coughs n=306); involuntary coughing patients, n=15 (coughs n=15).
188 c, concentration; D_p, particle diameter; N, particle number
189

190 DISCUSSION

191 In this study we defined a quantitative estimate for high-risk AGP when assessing the risk of
192 exposure of OR staff. By considering the time spent on the OR, as well as the risk of the patient's
193 possible airborne disease, a rough risk assessment of the staff's risk during the procedure was
194 formed. As information on the pathogens contained in aerosol particles as well as infectious doses
195 of airborne diseases increases, these factors can later replace the role of coughing in the risk
196 assessment. Our methodology provides a numeric limit value for the exposure faced by a staff
197 member in an OR environment already considering the environmental factors that affect aerosol
198 dispersion in the space. Thus, the values we measured can be used as a reference when assessing
199 other AGPs that OR staff are exposed to [24].

200 Our results in relation to the aerosol concentration generated by coughing and the role of coughing
201 as an aerosol generating behaviors (AGBs) are in a line with a recent systematic review. However,

202 we have a higher number of records, we made the systematic distance-dependent evaluation, and
203 we systematically determined aerosol concentrations, which collectively strengthen our study [25].
204 In our study, the highest aerosol concentrations were observed at 100 cm distance. This is probably
205 due to the methodology: the flow rate of OPS is 1l/min. When measuring particles with high
206 acceleration at close range, some particles bypass the device and are not recorded. When distance
207 increases further, the acceleration of the particles is reduced, and they are observed more accurately.
208 However, OPS is currently the most suitable and used measuring device, especially in OR
209 conditions, so when examining the generation of aerosols during surgical procedures its use is
210 justified despite the limitations.

211 The large range and personal differences of the particle concentrations observed in our study is
212 naturally seen in different respiratory activities and related to heterogeneity of the cough[26].
213 However, taking into account similar concentrations of volitional and involuntary coughs, we can
214 state that the presented data is well representative of the average aerosol concentrations generated
215 during coughing. A previous study of Lee et al. showed that infected patients generated a greater
216 number of particles when coughing compared to the healthy ones[27]. Thus, it could be stated that
217 the particle concentration seen in our results is the minimum value to determine the limit of AGP.

218 Whether the definition for AGP is useful at all can be discussed. Understanding humans as aerosol
219 generators during normal respiratory activities has grown and the term aerosol generating behaviors
220 (AGBs) are proposed alongside the AGP [25] However, statistics from around the world show that
221 surgeries involving mucus membranes and respiratory track area were significantly reversed during
222 the COVID-19 pandemic due to the fear of infection. Thus, quantitative variables used for risk
223 assessment are a step forward from previous intuitive measures toward more comprehensive risk
224 assessment.

225 **CONCLUSION** This study provides a standard for aerosol concentration and size distribution for
226 aerosols generated when coughing to act as reference for high-risk aerosol generation during
227 surgical procedures performed in the OR.

228 **ACKNOWLEDGMENTS** We thank Catharina Pomoell for her great work as a research nurse.

229 **CONFLICT OF INTEREST DISCLOSURES:** None of the authors has any financial or other
230 relationships that might lead to a conflict of interest.

231 **INFORMED CONSENT:** All patients provided written informed consent prior to participating in
232 the study.

233 **FUNDING:** NA

234 **ROLES OF AUTHORS BASED ON ICJME STANDARDS:** All authors have approved the
235 manuscript and have made significant contributions:

236 Conceptualization (ES, LMO, VJA, LL); methodology (ES, LMO, APH, VJA, AG); validation (ES,
237 LMO, APH); formal analysis (ES, LOM, NR, ML, APH); investigation (ES, LMO, NR); resources
238 (ES, AG); writing original draft (ES); writing – review & editing (LMO, NR, ML, APH, LL, VJA,
239 AG); visualization (NR, ML); editing (ES); project administration (ES, LMO, AG; VJA); funding
240 (ES; APH; AG)

241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257

258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288

REFERENCES

- 289 1. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis.
290 Nat Rev Dis Primers. 2016;2:16076. Epub 2016/10/28. doi: 10.1038/nrdp.2016.76. PubMed PMID:
291 27784885.
- 292 2. Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ
293 Med. 2015;57(5):501-8. Epub 2015/03/31. doi: 10.1097/JOM.0000000000000448. PubMed PMID:
294 25816216.
- 295 3. Cowling BJ, Ip DK, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al. Aerosol
296 transmission is an important mode of influenza A virus spread. Nat Commun. 2013;4:1935. Epub
297 2013/06/06. doi: 10.1038/ncomms2922. PubMed PMID: 23736803; PubMed Central PMCID:
298 PMC3682679.
- 299 4. Morawska L, Tang JW, Bahnfleth W, Bluysen PM, Boerstra A, Buonanno G, et al.
300 How can airborne transmission of COVID-19 indoors be minimised? Environ Int.
301 2020;142:105832. Epub 2020/06/11. doi: 10.1016/j.envint.2020.105832. PubMed PMID:
302 32521345; PubMed Central PMCID: PMC7250761 competing financial interests or personal
303 relationships that could have appeared to influence the work reported in this paper.
- 304 5. Arman S, Hopkins M, McKean S. The impact of COVID-19 on elective
305 otolaryngology surgery in a rural hospital in the United Kingdom. Clin Otolaryngol. 2021. Epub
306 2021/06/27. doi: 10.1111/coa.13830. PubMed PMID: 34174165.

- 307 6. Givi B, Moore MG, Bewley AF, Coffey CS, Cohen MA, Hessel AC, et al. Advanced
308 head and neck surgery training during the COVID-19 pandemic. *Head Neck*. 2020;42(7):1411-7.
309 Epub 2020/05/10. doi: 10.1002/hed.26252. PubMed PMID: 32383550.
- 310 7. Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, et al. COVID-19
311 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck
312 surgery practice. *Head Neck*. 2020;42(6):1259-67. Epub 2020/04/10. doi: 10.1002/hed.26164.
313 PubMed PMID: 32270581; PubMed Central PMCID: PMC7262203.
- 314 8. Vuorinen V, Aarnio M, Alava M, Alopaeus V, Atanasova N, Auvinen M, et al.
315 Modelling aerosol transport and virus exposure with numerical simulations in relation to SARS-
316 CoV-2 transmission by inhalation indoors. *Saf Sci*. 2020;130:104866. Epub 2020/08/25. doi:
317 10.1016/j.ssci.2020.104866. PubMed PMID: 32834511; PubMed Central PMCID:
318 PMC7428778.
- 319 9. Fernstrom A, Goldblatt M. Aerobiology and its role in the transmission of infectious
320 diseases. *J Pathog*. 2013;2013:493960. Epub 2013/02/01. doi: 10.1155/2013/493960. PubMed
321 PMID: 23365758; PubMed Central PMCID: PMC3556854.
- 322 10. Lindsley WG, Blachere FM, Thewlis RE, Vishnu A, Davis KA, Cao G, et al.
323 Measurements of airborne influenza virus in aerosol particles from human coughs. *PLoS One*.
324 2010;5(11):e15100. Epub 2010/12/15. doi: 10.1371/journal.pone.0015100. PubMed PMID:
325 21152051; PubMed Central PMCID: PMC2994911.
- 326 11. Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, et al. Detection
327 of *Mycobacterium tuberculosis* bacilli in bio-aerosols from untreated TB patients. *Gates Open Res*.
328 2017;1:11. Epub 2018/06/08. doi: 10.12688/gatesopenres.12758.2. PubMed PMID: 29355225;
329 PubMed Central PMCID: PMC5757796.
- 330 12. Fennelly KP, Jones-López EC, Ayakaka I, Kim S, Menyha H, Kirenga B, et al.
331 Variability of infectious aerosols produced during coughing by patients with pulmonary
332 tuberculosis. *American journal of respiratory and critical care medicine*. 2012;186(5):450-7.
- 333 13. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of
334 SARS-CoV-2 in two Wuhan hospitals. *Nature*. 2020;582(7813):557-60. Epub 2020/04/28. doi:
335 10.1038/s41586-020-2271-3. PubMed PMID: 32340022.
- 336 14. Chia PY, Coleman KK, Tan YK, Ong SWX, Gum M, Lau SK, et al. Detection of air
337 and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat Commun*.
338 2020;11(1):2800. Epub 2020/05/31. doi: 10.1038/s41467-020-16670-2. PubMed PMID: 32472043;
339 PubMed Central PMCID: PMC7260225.
- 340 15. Lednicky JA, Lauzardo M, Alam MM, Elbadry MA, Stephenson CJ, Gibson JC, et al.
341 Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. *Int J*
342 *Infect Dis*. 2021;108:212-6. Epub 2021/04/27. doi: 10.1016/j.ijid.2021.04.063. PubMed PMID:
343 33901650; PubMed Central PMCID: PMC8064821.
- 344 16. Abbey H. An examination of the Reed-Frost theory of epidemics. *Human biology*.
345 1952;24(3):201.
- 346 17. Lagos AE, Ramos PH, Andrade T. Protection for Otolaryngologic Surgery in the
347 COVID-19 Pandemic. *OTO Open*. 2020;4(2):2473974X20934734. Epub 2020/06/20. doi:
348 10.1177/2473974X20934734. PubMed PMID: 32551408; PubMed Central PMCID:
349 PMC7281886.
- 350 18. Krajewska J, Krajewski W, Zub K, Zatonski T. COVID-19 in otolaryngologist
351 practice: a review of current knowledge. *Eur Arch Otorhinolaryngol*. 2020;277(7):1885-97. Epub
352 2020/04/20. doi: 10.1007/s00405-020-05968-y. PubMed PMID: 32306118; PubMed Central
353 PMCID: PMC7166003.
- 354 19. Organization WH.
355 Transmission of SARS-CoV-2: implications for infection prevention precautions 2020 [updated 9
356 July 2020; cited 2020 9 July 2020].

- 357 20. Brown J, Gregson FKA, Shrimpton A, Cook TM, Bzdek BR, Reid JP, et al. A
358 quantitative evaluation of aerosol generation during tracheal intubation and extubation.
359 Anaesthesia. 2021;76(2):174-81. Epub 2020/10/07. doi: 10.1111/anae.15292. PubMed PMID:
360 33022093; PubMed Central PMCID: PMCPMC7675579.
- 361 21. Lindsley WG, King WP, Thewlis RE, Reynolds JS, Panday K, Cao G, et al.
362 Dispersion and exposure to a cough-generated aerosol in a simulated medical examination room. J
363 Occup Environ Hyg. 2012;9(12):681-90. Epub 2012/10/05. doi: 10.1080/15459624.2012.725986.
364 PubMed PMID: 23033849; PubMed Central PMCID: PMCPMC4688889.
- 365 22. Jackson T, Deibert D, Wyatt G, Durand-Moreau Q, Adisesh A, Khunti K, et al.
366 Classification of aerosol-generating procedures: a rapid systematic review. BMJ Open Respir Res.
367 2020;7(1). Epub 2020/10/12. doi: 10.1136/bmjresp-2020-000730. PubMed PMID: 33040021;
368 PubMed Central PMCID: PMCPMC7549490.
- 369 23. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing
370 under dependency. Annals of statistics. 2001;11:165-88.
- 371 24. Prather KA, Marr LC, Schooley RT, McDiarmid MA, Wilson ME, Milton DK.
372 Airborne transmission of SARS-CoV-2. Science. 2020;370(6514):303-4. Epub 2020/10/07. doi:
373 10.1126/science.abf0521. PubMed PMID: 33020250.
- 374 25. Chacon AM, Nguyen DD, McCabe P, Madill C. Aerosol-generating behaviours in
375 speech pathology clinical practice: A systematic literature review. PLoS One.
376 2021;16(4):e0250308. Epub 2021/04/29. doi: 10.1371/journal.pone.0250308. PubMed PMID:
377 33909654.
- 378 26. Mazzone SB, Farrell MJ. Heterogeneity of cough neurobiology: Clinical implications.
379 Pulm Pharmacol Ther. 2019;55:62-6. Epub 2019/02/15. doi: 10.1016/j.pupt.2019.02.002. PubMed
380 PMID: 30763726.
- 381 27. Jinho Lee DY, Seunghun Ryu, Seunghon Ham, Kiyong Lee, Myoungsok Yeo,
382 Kyoungbok Min, Chungsik Yoon Quantity, Size Distribution, and Characteristics of Cough-
383 generated Aerosol Produced by Patients with an Upper Respiratory Tract Infection. Aerosol and Air
384 Quality Research. 2019;19(4):840-53. doi: <https://doi.org/10.4209/aaqr.2018.01.0031>
385

386

387 .

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436

437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452

